News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

GENFIT Corp. (ALGFT) Release: Minutes Of The Annual General Meeting Of June 20, 2014


6/23/2014 9:06:27 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Lille (France), Boston (Massachusetts, United States), June 23, 2014 - GENFIT (Euronext:GNFT; ISIN:FR0004163111), a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions in metabolic and inflammatory diseases, that notably affect the liver or the gastrointestinal system, today announces that its shareholders have voted in favor of the totality of the proposed resolutions during the Annual General Meeting of Shareholders ("AGM") that was held in Lille on June 20, 2014.

The shareholders approved all the resolutions by a large majority of at least 90% of the cast votes.

Jean-François Mouney, Chairman and Chief Executive Officer of GENFIT, declared: «This AGM took place in the presence of a number of historical shareholders, and individual investors were strongly represented. The absence of exceptional motions in the agenda enabled us to devote time to the development of our scientific and medical strategy. It was the occasion to show that, in addition to the strong potential of GFT505 in NASH, several other programs contribute to the future development of the Company ».

About GENFIT:

GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in fields of high medical need due to a lack of suitable treatment and an increasing number of patients worldwide. GENFIT's R&D efforts are focused on contributing to bringing new medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases, that affect the liver (such as NASH - Nonalcoholic steatohepatitis) or the bowel (such as the inflammatory bowel disease). GENFIT implements mutually beneficial approaches that combine novel treatments and biomarkers; its research programs have resulted in the creation of a rich and diversified pipeline of drug candidates, including GENFIT's lead proprietary compound, GFT505, that is completing a Phase 2b study in NASH.

With facilities in Lille, France, and Boston, MA (USA), the Company has approximately 80 employees. GENFIT is a public company listed in compartment B of Euronext's regulated market in Paris (Euronext: GNFT; ISIN: FR0004163111). www.genfit.com

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES